Navigation Links
FDA Approves First Additive Solution for Platelet Storage Up to 5 Days

SILVER SPRING, Md., Dec. 10 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved InterSol, the first solution approved to replace a portion of plasma used when storing platelets for up to five days, allowing some of the donor plasma to be used for other purposes.


In the United States, platelets, which are blood components that help with blood clotting, have been stored in donor plasma. About 65% of that plasma is replaced with the InterSol platelet additive solution.

Platelets are used to prevent or treat bleeding in individuals undergoing chemotherapy for cancer, after major trauma, during or after surgery, and in individuals who do not produce platelets. InterSol solution does not have a therapeutic effect by itself but acts to provide nutrients and an appropriate environment in which to store platelets.

"The approval of InterSol is a significant step in the development and marketing of novel processes for the storage of platelets," said Karen Midthun, MD, acting director of FDA's Center for Biologics Evaluation and Research.

The InterSol platelet additive solution is an aqueous solution of various salt components. It replaces a proportion of plasma in the storage of platelets collected by an automated instrument.

InterSol solution is manufactured by Fenwal Inc., Lake Zurich, IL.

Draft: OBRR, 10/19/09
Edits: W. J. Gardner, 10/20/09
Edits: D. Bartell, 10/20/09
Edits: L. McNeill, 10/20/09
Revised: D. Bartell, 10/20/09
Edits: S. Burgess, 10/26/09
Edits: G. Michaud, 10/26/09
CBER Clearance: D. Maloney, 10/27/09
Edits/Clearance: OPA, 10/30/09
Comments: M. Robinson, HHS, 11/27/09
Edits: W. Gardner, 11/30/09
Edits: H. Salim, 11/30/09
Edits and CBER Clearance: B. Yetter, 12/1/09
Edits: N. Jain, 12/1/09
Review/Clearance: G. Michaud, 12/1/09

Media Inquiries: Shelly Burgess, 301-796-4651,
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Approves New Stem Cell Lines for Publicly Funded Research
2. State Approves Plans For Kidney Transplants At Advocate Christ Medical Center
3. FDA Approves New Treatment for Chronic Lymphocytic Leukemia
4. CMS Approves Press Ganey as a Qualified Home Health Care CAHPS Survey Vendor
5. FDA Approves PRE-PEN Penicillin Allergy Test
6. FDA Approves Donor Screening Test for Antibodies to HIV
7. ClearWay Minnesota(SM) Board Approves New Officers
8. FDA Approves Vaccines for 2009 H1N1 Influenza Virus
9. FDA Approves 4 Swine Flu Vaccines
10. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
11. FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Post Your Comments:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology: